Prime Medicine (PRME) Non-Current Deffered Revenue (2024 - 2026)
Prime Medicine's (PRME) quarterly Non-Current Deffered Revenue came in at $57.8 million in Q1 2026, down 4.75% YoY from $60.7 million in Q1 2025, and down 0.61% on a QoQ basis from $58.1 million in Q4 2025.
Prime Medicine (PRME) Non-Current Deffered Revenue (2024 - 2026) Analysis & Trends
Prime Medicine (PRME) has 3 years of Non-Current Deffered Revenue data on file, last reported at $57.8 million in Q1 2026.
- Quarterly Non-Current Deffered Revenue fell 4.75% year-over-year to $57.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $57.8 million (down 4.75% YoY) and the FY2025 annual result came in at $58.1 million, down 8.05% from the prior year.
- Non-Current Deffered Revenue slipped to $57.8 million in Q1 2026, from $58.1 million in the prior quarter.
- In the past five years, Non-Current Deffered Revenue ranged from a high of $63.2 million in Q4 2024 to a low of $57.8 million in Q1 2026.
- A 3-year average of $60.2 million and a median of $59.8 million in 2025 frame the typical range for Non-Current Deffered Revenue.
- The widest YoY moves for Non-Current Deffered Revenue: up 4.61% in 2025, down 8.05% in 2025.
- Tracing PRME's Non-Current Deffered Revenue over 3 years: stood at $63.2 million in 2024, then dropped by 8.05% to $58.1 million in 2025, then declined by 0.61% to $57.8 million in 2026.
- The last three Non-Current Deffered Revenue figures came in at $57.8 million (Q1 2026), $58.1 million (Q4 2025), and $59.8 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 220.40 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Prime Medicine | 558.48 Mn | 558.48 Mn | - | 56.03 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 56.03 Mn |
| Mar 31, 2026 | 57.78 Mn |
| Dec 31, 2025 | 58.13 Mn |
| Sep 30, 2025 | 59.75 Mn |
| Jun 30, 2025 | 59.56 Mn |
| Mar 31, 2025 | 60.66 Mn |
| Dec 31, 2024 | 63.22 Mn |
| Sep 30, 2024 | 62.64 Mn |